Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study

被引:16
|
作者
Zettl, Uwe K. [1 ]
Bauer-Steinhusen, Ulrike [2 ]
Glaser, Thomas [2 ]
Hechenbichler, Klaus [3 ]
Limmroth, Volker [4 ]
机构
[1] Univ Med Rostock, Klin & Poliklin Neurol, Rostock, Germany
[2] Bayer Vital GmbH, Immunol & Ophthalmol, Med Neurol, Leverkusen, Germany
[3] Inst Dr Schauerte, Oberhaching, Germany
[4] Stadt Klinikum Koln Merheim, Klin Neurol, Cologne, Germany
来源
BMC NEUROLOGY | 2013年 / 13卷
关键词
Adherence; Interferon beta-1b; Non-interventional study; Electronic diary; Multiple sclerosis; Immunomodulation; DEPRESSIVE SYMPTOMS; CES-D; THERAPY; POPULATION; VALIDATION; MEDICATION; IMPACT; COSTS; DRUGS; CARE;
D O I
10.1186/1471-2377-13-117
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis is a chronic, incurable, demyelinating disease that requires long-term treatment. Rates of non-adherence to prescribed therapy of up to 50% have been reported for chronic diseases. Strategies to improve treatment adherence are therefore of the utmost importance. This study will evaluate the effect of using electronic and paper diaries on treatment adherence to interferon beta-1b in patients with a first clinical isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS). Here we report on the study design and results of baseline assessments. Methods: Patients were recruited into a prospective national multicenter cohort study for an observational period of 2 years. At the start of the study, patients opted to use a digital (DiD) or paper diary (PD) to document self-administered injections of interferon beta-1b. Adherence to treatment will be assessed on the dropout rate at the end of the observation period and on the regularity of injections every other day at 6-month intervals. Patient-related health outcomes will also be evaluated. Results: 700 patients with a mean age of 38.3 (SD 10.3) years and a mean duration of disease since diagnosis of 3.6 (SD 5.9) years were enrolled. 383 patients opted for the digital diary, 192 of which included an injection reminder. Significantly more male than female patients opted for the DiD. Only gender was identified as a factor influencing the decision for DiD or PD. Based on rating scales, a significantly higher proportion of women had depressive comorbidities at baseline. Conclusions: Demographic characteristics of the two cohorts were similar at baseline. More women chose a paper diary, and more had depression at baseline. These imbalances will be addressed in the analysis of the study as possible confounders influencing long-term treatment adherence in the digital and paper diary cohorts.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The Effect of Interferon Beta-1b and Methylprednisolone Treatment on the Serum Trace Elements in Iraqi Patients with Multiple Sclerosis
    Al-Zubaidi, Mohammed A.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2012, 6 (06) : 994 - 998
  • [42] The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis
    Gaindh, Deeya
    Jeffries, Neal
    Ohayon, Joan
    Richert, Nancy D.
    Pellicano, Clelia
    Frank, Joseph A.
    McFarland, Henry
    Bagnato, Francesca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (12) : 1823 - 1829
  • [43] A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector
    Ryan Farej
    Mark Rametta
    Anneliese La Rose
    Apryl Quillen
    Kim McLeod
    Neurology and Therapy, 2022, 11 : 373 - 384
  • [44] Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis
    Edo Solsona, Maria Dolores
    Monte Boquet, Emilio
    Casanova Estruch, Bonaventura
    Poveda Andres, Jose Luis
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 415 - 421
  • [45] Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study
    Bayas, Antonios
    Ouallet, Jean Christophe
    Kallmann, Boris
    Hupperts, Raymond
    Fulda, Ulrich
    Marhardt, Kurt
    EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (08) : 1239 - 1250
  • [46] Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial
    Goodin, Douglas S.
    Hartung, Hans-Peter
    O'Connor, Paul
    Filippi, Massimo
    Arnason, Barry
    Comi, Giancarlo
    Cook, Stuart
    Jeffery, Douglas
    Kappos, Ludwig
    Bogumil, Timon
    Knappertz, Volker
    Sandbrink, Rupert
    Beckmann, Karola
    White, Rick
    Petkau, John
    Pohl, Christoph
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (02) : 181 - 195
  • [47] Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
    Durelli, L
    Oggero, A
    Verdun, E
    Isoardo, G
    Ricci, A
    Barbero, P
    Bergamasco, B
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 178 (01) : 37 - 41
  • [48] Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy
    Uwe Klaus Zettl
    Ulrike Bauer-Steinhusen
    Thomas Glaser
    Klaus Hechenbichler
    Michael Hecker
    BMC Neurology, 16
  • [49] Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain
    Arbizu, T
    Alvarez-Cermeño, JC
    Decap, G
    Fernández, O
    Uría, DF
    Merino, AG
    Izquierdo, G
    Montalbán, X
    ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 (04): : 209 - 217
  • [50] Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain
    Pinol, C.
    NEUROLOGIA, 2016, 31 (04): : 247 - 254